Pappas Ventures News Today

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is back on track with a potential drug to treat rapid heart rates in certain cardiovascular disorders.The company in late March re-submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of etripamil for the management of paroxysmal supraventricular tachycardia (PSVT), a type of arrhythmia or abnormal heart rhythm. 

There's another Pappas working at Pappas Capital, but the venture capital firm is quick to point out that Nick Pappas is "no relation" to the firm's founder Art Pappas.

/PRNewswire/ -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has...

Mianus Capital (Mianus) and its strategic partner MERIT CRO, Inc. (MERIT) announced at the Association for Research in Vision and Ophthalmology (ARVO) 2023

/PRNewswire/ -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner....

/PRNewswire/ -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and...

/PRNewswire/ -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and...